Ideeea Therapeutics
Biotech startup pioneering advanced therapy medicinal products (ATMPs) to revolutionize regenerative medicine and immunology.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | €2.3m | Seed | |
| Total Funding | 000k | ||
Related Content
Ideeea Therapeutics, established in 2020, is a clinical-stage biotechnology company focused on creating Advanced Therapy Medicinal Products (ATMPs). The company was founded by a team of healthcare executives from the Spanish pharmaceutical firm FARMALIDER, including Marisa Berenguer, who now serves as CEO, and José Ángel Sánchez, the Chief Innovation Officer. This venture leverages the founders' extensive experience in developing and marketing pharmaceutical products to address complex medical conditions with limited treatment options.
The company's business model is centered on an open innovation framework, collaborating with hospitals, research centers, and other startups to advance its product pipeline. Ideeea Therapeutics operates as a comprehensive partner, managing the entire value chain from initial concept and R&D to GMP-compliant manufacturing and commercialization. Its services are structured to support researchers and startups by co-developing and investing in new biotech products, providing expertise in intellectual property, regulatory affairs, and support for preclinical and clinical studies. The firm recently secured €2.3 million ($2.6M) in a seed funding round to advance its lead program.
Ideeea Therapeutics is developing treatments in regenerative and autoimmune medicine, with a portfolio that includes gene therapies, somatic-cell therapies, and tissue-engineered medicines. Its flagship preclinical program, AGAcell®, is an allogeneic cell therapy using mesenchymal stem cells to treat androgenetic alopecia, or pattern baldness. This product aims to regenerate hair follicles through a minimally invasive, non-surgical procedure by administering a proprietary formulation of stem cells. The program is scientifically led by Dr. Eduardo López Bran, a specialist in dermatology and trichology. By focusing on allogeneic (donor-derived) cells, the company aims to develop scalable and more accessible treatments for a wide range of patients.
Keywords: cell therapy, regenerative medicine, autoimmune diseases, ATMPs, androgenetic alopecia, allogeneic therapies, GMP manufacturing, open innovation, pharmaceutical development, biotechnology